Centene Corp (CNC)
Health Care · Managed Health Care · US stock · S&P 500 component
$69.16
▼ -1.35 (1.91%)
Fair valueData under review
$393
$197fair band $275–$511$590
Day's range
$69.02 – $71.21
52-week range
$31.63 – $71.21
About Centene Corp
Centene is a managed health care company that arranges and pays for medical coverage for people enrolled in government-sponsored programmes. Its main focus is Medicaid, and it also covers people through Medicare plans and the individual health insurance marketplace, where plans are offered under the Ambetter name. Members receive care through networks of doctors and hospitals that the company contracts with, and the company manages their claims and care coordination.
Revenue comes mainly from premiums paid by state and federal governments and by individuals, out of which the company pays its members' medical costs. In the last twelve months it totalled $202.9 billion, growing at 10.5% a year across the last three years. The operating margin is -2.8%, which means the business made an operating loss, and the return on the capital invested in it is -38%. No dividend is paid. On the site's X-Ray Score it receives 46 out of 100.
Written with AI from public information and the filing figures on this page, then checked automatically for unsupported numbers. It can contain mistakes: read the company's own filings below before relying on it.
Price chart
52-wk range $31.63 – $71.21Volume 3,336,600Daily, split-adjusted
Vitals
Market cap$34.4B
52-week range$31.63 – $71.21
Volume (last day)3,336,600
P/E (TTM)–
EBIT / EV yield-24.0%
Free-cash-flow yield26.0%
Dividend yieldNo dividend
Revenue (TTM)$202.9B
Net income (TTM)−$5.1B
Operating margin-2.8%
Return on capital-38.4%
Debt incl. leases$16.1B
Cash & securities$27.1B
Debt = borrowings plus lease liabilities. Cash & securities = cash, equivalents and short-term marketable securities (long-term securities are not counted, so net cash can be understated for companies like Apple). Net debt = debt minus cash & securities. Source: latest SEC 10-Q/10-K. EBIT / EV yield = operating profit divided by market cap plus net debt.
Fair value estimate
$393
Data under review
+0.0% to fair value
Equal blend of three models: peer multiples, a fundamentals-adjusted multiple (growth, ROIC and margin) and a 10-year DCF scaled to the market's average. Earnings-power value (no growth) is a floor and not part of the blend. Model uncertainty is Medium, so the safety margin is 30%.
Loss-making or insufficient history: no DCF/EPV
Price $69
Undervalued < $275Fair $275 – $511Overvalued > $511
Peer multiples
$393
A model estimate, not a price target or recommendation. Inputs: risk-free 5.09%, equity risk premium 4.23% (Damodaran). How it works.
What this means
Read the lenses below
The price sits inside our fair-value band. A high score does not guarantee a good outcome; it shifts the odds a little. Use the checklist as a prompt for your own research.
Before you invest · decision checklist
Ticked boxes are filled in from our data; the rest are yours to answer.
The five-lens scan
Every score explained in one sentence, ranked against Health Care peers. Open a lens to see the numbers behind it.
Valuation
Strong
73/100
Cheap against its sector on earnings and cash flow.
See the numbers →
EBIT / EV yield-24.0%
Free-cash-flow yield26.0%
Fair value vs price5.7×
Growth
Fair
65/100
Growing at a typical pace for its sector.
See the numbers →
Revenue growth (3y)10.5%
Growth consistency100%
Profitability
Weak
32/100
Earns lower returns on its capital than most peers.
See the numbers →
Return on invested capital-38.4%
Operating margin-2.8%
Gross profitability19.5%
Financial health
Weak
10/100
Balance sheet is more stretched than most peers.
See the numbers →
Piotroski F-Score4 / 9
Interest cover-8.6×
Dividends
None
–/100
Pays no dividend.
See the numbers →
Quarterly results: last 6 quarters
+15.4%
Mar '25
+22.4%
Jun '25
+18.2%
Sep '25
+21.9%
Dec '25
+7.1%
Mar '26
+9.9%
Jun '26
Revenue against the same quarter a year earlier. Latest quarter revenue $53.6B, diluted EPS $2.19.
Compare with peers
ELV Elevance Health, Inc.62 UNH Unitedhealth Group Inc59 HUM Humana Inc51Other Managed Health Care companies by X-Ray Score.
Fundamentals checklist
● 5 Good · ● 0 Average · ● 9 BadCash quality
Earnings backed by cashGood
Free-cash-flow yieldGood
Risk models
Altman Z''Bad
Piotroski F-ScoreBad
Growth
Free-cash-flow growth (3y)Bad
Revenue growth (3y)Good
Growth consistencyGood
Balance sheet
Current ratioBad
Interest coverBad
Valuation
Fair value vs priceGood
EBIT / EV yieldBad
Profitability
Return on invested capitalBad
Operating marginBad
Gross profitabilityBad
Each check is graded against the company's sector, not a fixed number. Checklist score 42/100.
Financials
| FY21 | FY22 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|
| Revenue | $126.0B | $144.5B | $154.0B | $163.1B | $194.8B |
| Operating income | $1.8B | $1.3B | $2.9B | $3.2B | −$7.6B |
| Net income | $1.3B | $1.2B | $2.7B | $3.3B | −$6.7B |
| Operating cash flow | $4.2B | $6.3B | $8.1B | $154M | $5.1B |
| Operating margin | 1.4% | 0.9% | 1.9% | 1.9% | -3.9% |
| Free cash flow | $3.3B | $5.3B | $7.3B | −$490M | $4.3B |
| Diluted EPS | $2.28 | $2.07 | $4.95 | $6.31 | $-13.53 |
Fiscal years, from SEC filings.
Technical summary
Daily
Strongly bullish
12 bullish · 1 neutral · 3 bearish
Weekly
Strongly bullish
11 bullish · 1 neutral · 0 bearish
Monthly
Strongly bullish
7 bullish · 1 neutral · 0 bearish
Moving averages (daily)
| SMA 10 | 66.95 | Bullish |
| EMA 10 | 67.42 | Bullish |
| SMA 20 | 64.72 | Bullish |
| EMA 20 | 66.16 | Bullish |
| SMA 50 | 65.39 | Bullish |
| EMA 50 | 65.11 | Bullish |
| SMA 100 | 64.77 | Bullish |
| EMA 100 | 62.39 | Bullish |
| SMA 200 | 54.15 | Bullish |
| EMA 200 | 57.17 | Bullish |
Oscillators (daily)
| RSI (14) | 62.45 | Neutral |
| MACD (12, 26) | 1.19 | Bullish |
| Momentum (12) | 11.33 | Bullish |
| Stochastic %K (14) | 82.55 | Bearish |
| Williams %R (14) | -17.45 | Bearish |
| CCI (20) | 147.1 | Bearish |
Pivot points (classic, last session)
S3 66.19 | S2 67.61 | S1 68.38 | Pivot 69.80 | R1 70.57 | R2 71.99 | R3 72.76 |
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
CNC SEC filings
8 Oct 2026
8-KSEC EDGAR
Other events
16 Sep 2026
8-KSEC EDGAR
Regulation FD disclosure
17 Aug 2026
8-KSEC EDGAR
Director or officer change; Regulation FD disclosure
29 Jul 2026
8-KSEC EDGAR
Other events
28 Jul 2026
8-KSEC EDGAR
Results of operations; Director or officer change
28 Jul 2026
10-QSEC EDGAR
Quarterly report
22 Jun 2026
8-KSEC EDGAR
Director or officer change; Regulation FD disclosure
15 May 2026
8-KSEC EDGAR
Director or officer change; Shareholder vote results
Where the numbers come from
Statements SEC EDGAR filings (10-K, 10-Q), quarters derived from year-to-date figures.
Prices end-of-day closes, split-adjusted.
Industry inputs beta, multiples and equity risk premium from Damodaran Online (NYU Stern).
StocksXray is for education only and is not financial advice. Scores and fair values are model estimates from public filings and carry uncertainty.